{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:05:26Z","timestamp":1790622326264,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>Schizophrenia is a serious mental disorder that affects 1% of the world\u2019s population. Although various therapeutic tools have been developed since the appearance of the first generation of antipsychotics, the effect of these agents does not manage to attenuate a significant part of psychotic symptoms. Ketamine is an anesthetic agent able to produce psychotic-like symptoms through the antagonism of the glutamatergic <jats:italic toggle=\"yes\">N<\/jats:italic>-methyl-<jats:sc>d<\/jats:sc>-aspartic acid (NMDA) receptors (NMDARs). This drug has been widely used to study new pharmacological tools with potential antipsychotic properties. On the contrary, it is known that the 5-HT<jats:sub>6<\/jats:sub> receptor agonist and antagonist drugs induce procognitive, anxiolytic and antidepressant effects in different preclinical models. Therefore, the aim of this study was to evaluate the behavioral actions of the 5-HT<jats:sub>6<\/jats:sub> receptors\u2019 agonist E-6837 and the antagonist SB-271046, in ICR-CD1 mice previously treated with a subchronic ketamine scheme (10 mg\/kg i.p. daily for 5 days). Results showed that repeated administration of ketamine induced recognition memory deficit, anxiogenic effects, obsessive-compulsive behaviors and stereotyped movements. The acute administration of both 5-HT<jats:sub>6<\/jats:sub> agents reversed the memory deficit and induced a decrease in anxiety, whereas SB-271046 administration produced a decrease in climbing behavior. The injection of either of these 5-HT<jats:sub>6<\/jats:sub> drugs had no effect in the light\u2013dark test. Surprisingly, when these drugs were injected together with ketamine, anxiogenic actions were produced. Current findings suggest that both agonist and antagonist 5-HT<jats:sub>6<\/jats:sub> drugs play an important role in modulating psychotic-like symptoms induced by the subchronic blockade of NMDAR.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000669","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T08:05:59Z","timestamp":1644221159000},"page":"249-254","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["The 5-HT6R agonist E-6837 and the antagonist SB-271046 reverse the psychotic-like behaviors induced by ketamine"],"prefix":"10.1097","volume":"33","author":[{"given":"Jos\u00e9 Eduardo","family":"Su\u00e1rez-Santiago","sequence":"first","affiliation":[{"name":"Departamento de Fisiolog\u00eda, Facultad de Medicina, Universidad Nacional Aut\u00f3noma de M\u00e9xico"},{"name":"Laboratorio de Farmacolog\u00eda Conductual, Escuela Superior de Medicina, Instituto Polit\u00e9cnico Nacional, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Rold\u00e1n Rold\u00e1n","sequence":"additional","affiliation":[{"name":"Departamento de Fisiolog\u00eda, Facultad de Medicina, Universidad Nacional Aut\u00f3noma de M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofir","family":"Picazo Picazo","sequence":"additional","affiliation":[{"name":"Laboratorio de Farmacolog\u00eda Conductual, Escuela Superior de Medicina, Instituto Polit\u00e9cnico Nacional, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1139\/cjpp-2014-0254","article-title":"Low-dose prazosin in combination with 5-HT6 antagonist PRX-07034 has antipsychotic effects.","volume":"93","author":"Abraham","year":"2015","journal-title":"Can J Physiol Pharmacol"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.physbeh.2016.06.017","article-title":"Pre-training in a radial arm maze abolished anxiety and impaired habituation in C57BL6\/J mice treated with dizocilpine.","volume":"164","author":"Abuhamdah","year":"2016","journal-title":"Physiol Behav"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuroscience.2015.11.009","article-title":"Using mice to model obsessive compulsive disorder: from genes to circuits.","volume":"321","author":"Ahmari","year":"2016","journal-title":"Neuroscience"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bbr.2018.11.021","article-title":"Intrahippocampal administration of 5-HT6 receptor drugs on memory consolidation and amnesia protocols.","volume":"359","author":"Aparicio-Nava","year":"2019","journal-title":"Behav Brain Res"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"111928","DOI":"10.1016\/j.bbr.2019.111928","article-title":"Long-lasting effects of repeated ketamine administration in adult and adolescent rats.","volume":"369","author":"Bates","year":"2019","journal-title":"Behav Brain Res"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.brainresbull.2018.03.006","article-title":"Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.","volume":"139","author":"Ben-Azu","year":"2018","journal-title":"Brain Res Bull"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00213-018-4866-z","article-title":"5-HT6 receptor agonist and antagonist modulates ICV-STZ-induced memory impairment in rats.","volume":"235","author":"Bokare","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/FBP.0000000000000235","article-title":"Effect of ketamine administration, alone and in combination with E-6837, on climbing behavior.","volume":"27","author":"Briones-Aranda","year":"2016","journal-title":"Behav Pharmacol"},{"issue":"Suppl 2","key":"R9-20250614","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1590\/1516-4446-2013-1139","article-title":"Animal models of anxiety disorders and stress.","volume":"35","author":"Campos","year":"2013","journal-title":"Braz J Psychiatry"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0091-3057(80)90067-2","article-title":"Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines.","volume":"13","author":"Crawley","year":"1980","journal-title":"Pharmacol Biochem Behav"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41386-019-0328-5","article-title":"Reduced auditory evoked gamma-band response and schizophrenia-like clinical symptoms under subanesthetic ketamine.","volume":"44","author":"Curic","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"5452727","DOI":"10.1155\/2019\/5452727","article-title":"\u201cSpecial K\u201d drug on adolescent rats: oxidative damage and neurobehavioral impairments.","volume":"2019","author":"de Carvalho Cart\u00e1genes","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4196\/kjpp.2009.13.2.71","article-title":"YKP1447, a novel potential atypical antipsychotic agent.","volume":"13","author":"Dong","year":"2009","journal-title":"Korean J Physiol Pharmacol"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejphar.2008.01.035","article-title":"Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder.","volume":"586","author":"Egashira","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"R15a-20250614","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data.","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behav Brain Res"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.physbeh.2014.05.032","article-title":"Tests of unconditioned anxiety: pitfalls and disappointments.","volume":"135","author":"Ennaceur","year":"2014","journal-title":"Physiol Behav"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00213-013-3234-2","article-title":"Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats.","volume":"231","author":"Fija\u0142","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1021\/acschemneuro.8b00618","article-title":"Dual 5-HT6 and D3 receptor antagonists in a group of 1H-pyrrolo[3,2-c]quinolines with neuroprotective and procognitive activity.","volume":"10","author":"Grychowska","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"R18-20250614","first-page":"205","article-title":"Movement disorders is psychiatric diseases.","volume":"16","author":"Hidasi","year":"2014","journal-title":"Neuropsychopharmacol Hung"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3233\/JAD-161262","article-title":"AVN-492, a novel highly selective 5-HT6R antagonist: preclinical evaluation.","volume":"58","author":"Ivachtchenko","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.pharep.2018.05.009","article-title":"Chronic antidepressant-like effect of EMD386088, a partial 5-HT(6) receptor agonist, in olfactory bulbectomy model may be connected with BDNF and\/or CREB signalling pathway.","volume":"6","author":"Jastrz\u0119bska-Wi\u0119sek","year":"2018","journal-title":"Pharmacol Rep"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbr.2015.01.010","article-title":"Ketamine administration during the second postnatal week induces enduring schizophrenia-like behavioral symptoms and reduces parvalbumin expression in the medial prefrontal cortex of adult mice.","volume":"282","author":"Jeevakumar","year":"2015","journal-title":"Behav Brain Res"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1176\/appi.ajp.2014.14010004","article-title":"Lower expression of glutamic acid decarboxylase 67 in the prefrontal cortex in schizophrenia: contribution of altered regulation by Zif268.","volume":"171","author":"Kimoto","year":"2014","journal-title":"Am J Psychiatry"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13104-015-1062-7","article-title":"Analytical strategies for the marble burying test: avoiding impossible predictions and invalid p-values.","volume":"8","author":"Lazic","year":"2015","journal-title":"BMC Res Notes"},{"key":"R25-20250614","first-page":"1","article-title":"Activation and blockade of dorsal hippocampal Serotonin (6) receptors regulate anxiety-like behaviors in a unilateral 6-hydroxydopamine rat model of Parkinson\u2019s disease.","volume":"6","author":"Liu","year":"2019","journal-title":"Neurol Res"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.brainres.2016.09.009","article-title":"Activation and blockade of serotonin6 receptors in the dorsal hippocampus enhance T maze and hole-board performance in a unilateral 6-hydroxydopamine rat model of Parkinson\u2019s disease.","volume":"1650","author":"Liu","year":"2016","journal-title":"Brain Res"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00213-007-0934-5","article-title":"Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex.","volume":"196","author":"Loiseau","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"R28-20250614","first-page":"55718","article-title":"Novel object recognition test for the investigation of learning and memory in mice.","volume":"126","author":"Lueptow","year":"2017","journal-title":"J Vis Exp"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ddr.21337","article-title":"Improving current treatments for schizophrenia.","volume":"77","author":"Maric","year":"2016","journal-title":"Drug Dev Res"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/0269881113480991","article-title":"The 5-hydroxytryptamine (serotonin) receptor 6 agonist EMD 386088 ameliorates ketamine-induced deficits in attentional set shifting and novel object recognition, but not in the prepulse inhibition in rats.","volume":"27","author":"Nikiforuk","year":"2013","journal-title":"J Psychopharmacol"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/FBP.0000000000000414","article-title":"SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization.","volume":"30","author":"Nirogi","year":"2019","journal-title":"Behav Pharmacol"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia.","volume":"33","author":"Olney","year":"1999","journal-title":"J Psychiatr Res"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchemneu.2018.12.002","article-title":"Subchronic ketamine alters behaviour, metabolic indices and brain morphology in adolescent rats: involvement of oxidative stress, glutamate toxicity and caspase-3-mediated apoptosis.","volume":"96","author":"Onaolapo","year":"2019","journal-title":"J Chem Neuroanat"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00210-016-1229-3","article-title":"ADN-1184, a monoaminergic ligand with 5-HT6\/7 receptor antagonist action, exhibits activity in animal models of anxiety.","volume":"389","author":"Partyka","year":"2016","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fphar.2015.00200","article-title":"5-HT6 receptor agonism facilitates emotional learning.","volume":"6","author":"Pereira","year":"2015","journal-title":"Front Pharmacol"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s11064-018-02715-y","article-title":"Effects of anesthetic ketamine on anxiety-like behaviour in rats.","volume":"44","author":"Pitsikas","year":"2019","journal-title":"Neurochem Res"},{"key":"R38-20250614","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pbb.2016.12.014","article-title":"Dose-response characteristics of intravenous ketamine on dissociative stereotypy, locomotion, sensorimotor gating, and nociception in male Sprague-Dawley rats.","volume":"153","author":"Radford","year":"2017","journal-title":"Pharmacol Biochem Behav"},{"key":"R39-20250614","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbr.2015.10.060","article-title":"GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.","volume":"299","author":"Rajagopal","year":"2016","journal-title":"Behav Brain Res"},{"key":"R40-20250614","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/sj.npp.1301503","article-title":"Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466.","volume":"33","author":"Schechter","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R41-20250614","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/FBP.0000000000000327","article-title":"Agonist E-6837 and antagonist SB-271046 of 5-HT6 receptors both reverse the depressive-like effect induced in mice by subchronic ketamine administration.","volume":"28","author":"Su\u00e1rez-Santiago","year":"2017","journal-title":"Behav Pharmacol"},{"key":"R42-20250614","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neuropharm.2018.05.016","article-title":"Activation and blockade of basolateral amygdala 5-HT6 receptor produce anxiolytic-like behaviors in an experimental model of Parkinson\u2019s disease.","volume":"137","author":"Sun","year":"2018","journal-title":"Neuropharmacology"},{"key":"R43-20250614","first-page":"269","article-title":"Marble burying as compulsive behaviors in with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats.","volume":"1","author":"Taylor","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"R44-20250614","doi-asserted-by":"crossref","first-page":"736483","DOI":"10.3389\/fgene.2021.736483","article-title":"Peripheral blood-based gene expression studies in schizophrenia: a systematic review.","volume":"12","author":"Wagh","year":"2021","journal-title":"Front Genet"},{"key":"R45-20250614","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.neulet.2015.03.066","article-title":"Hyperactivity and disruption of prepulse inhibition induced by NMDA infusion of the rat ventral hippocampus: comparison of uni- and bilateral stimulation.","volume":"594","author":"Wang","year":"2015","journal-title":"Neurosci Lett"},{"key":"R46-20250614","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pbb.2019.04.002","article-title":"Comparison of the effects of 1MeTIQ and olanzapine on performance in the elevated plus maze test and monoamine metabolism in the brain after ketamine treatment.","volume":"181","author":"W\u0105sik","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"R47-20250614","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0706743718773728","article-title":"An overview of animal models related to schizophrenia.","volume":"64","author":"Winship","year":"2019","journal-title":"Can J Psychiatry"},{"key":"R48-20250614","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jpsychires.2015.02.013","article-title":"The myelinated fiber loss in the corpus callosum of mouse model of schizophrenia induced by MK-801.","volume":"63","author":"Xiu","year":"2015","journal-title":"J Psychiatr Res"},{"key":"R49-20250614","doi-asserted-by":"crossref","first-page":"818","DOI":"10.12659\/MSM.899067","article-title":"Effect of selective 5-HT6R agonist on expression of 5-HT receptor and neurotransmitter in vascular dementia rats.","volume":"23","author":"Yu","year":"2017","journal-title":"Med Sci Monit"},{"key":"R50-20250614","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuropharm.2019.04.001","article-title":"The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts behavioural deficits induced by the NMDA receptor antagonist ketamine in rats.","volume":"151","author":"Zoupa","year":"2019","journal-title":"Neuropharmacology"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:01:27Z","timestamp":1749938487000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000669","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,4]]}}}